Response to the Letter to the Editor “Advancing Clinical and Ethical Dimensions of Deep Learning in Cardiovascular Imaging” Authors: Amogh Verma, Prerna Uniyal, Sayanti Pandey Banerjee Published: 2025 Dear Editor, We thank the authors of the commentary on our article titled “Deep Learning for Early Detection of Cardiovascular Diseases From Medical Imaging” and their thoughtful engagement with our work published in Health Science Reports [1]. We appreciate the recognition of the technical rigor and diagnostic performance of our convolutional neural network–based approach and welcome the opportunity to address the constructive insights raised. The concern regarding the single‐institution nature of the EchoNet‐Dynamic data set is well taken. While our study explicitly acknowledges the need for multicenter validation, we agree that operational strategies, such as domain adaptation or federated learning, would enrich future iterations of our work. Our ongoing efforts include pilot testing on the Cardiac Acquisitions for Multi‐structure Ultrasound Segmentation (CAMUS) data set to examine cross‐center robustness and implement model recalibration pipelines to mitigate acquisition‐specific biases. These steps are already underway and will be formally reported in a subsequent study focusing on external validations. The binary classification threshold for left ventricular ejection fraction (LVEF) has raised critical discussions in cardiac imaging research. Our choice to dichotomize LVEF at ≤ 40% was guided by the clinical standards for defining heart failure with reduced ejection fraction [2]. Nonetheless, we concur that incorporating nuanced gradations, including diastolic parameters and expert‐adjudicated labels, would enhance clinical accuracy. We are currently collaborating with cardiologists to generate a multilabel data set that integrates echocardiography, electrocardiography, and natriuretic peptide data to develop a more comprehensive classification schema. Regarding the importance of interpretability validation beyond Grad‐CAM. We fully support this view. In our forthcoming extension study, we are integrating Shapley Additive Explanations to quantify feature contributions and plan to conduct blinded cardiologist reviews to benchmark the fidelity of model‐highlighted regions against clinical annotations. These prospective validations aim to align our model with the explainability standards recommended by emerging clinical AI guidelines [3]. We appreciate the commentary's emphasis on workflow readiness, data governance, and ethical oversight. While our current study focused on technical proof‐of‐concept, we recognize the importance of transparency, accountability, and regulatory alignment. Our future work includes usability testing within a simulated clinical environment and the development of traceable audit logs within the inference pipeline to ensure algorithmic accountability of the model. Data privacy and fairness audits will be conducted under institutional review in accordance with GDPR‐equivalent protocols. Regarding deployment feasibility, we agree that reliance on high‐end GPU presents a barrier to widespread clinical adoption. While our initial model was trained on a Tesla V100 for optimal benchmarking, we are currently optimizing the model through pruning and quantization to enable inferences on mid‐range hardware and mobile health platforms. These efforts align with our long‐term goal of democratizing AI‐powered diagnostics for low‐resource settings. The suggestion to incorporate outcome‐oriented metrics, such as time‐to‐diagnosis or inter‐rater variability, is well received. Our team is preparing a follow‐up study that embeds the model into a prospective diagnostic workflow and measures its effect on clinical decision turnaround time, reader consistency, and diagnostic concordance. We believe that such implementation research is essential for transitioning from model accuracy to patient impact. Once again, we sincerely thank the commentators for their constructive observations and the editorial team for this opportunity to respond. We remain committed to refining and validating our model in line with the best practices in clinical artificial intelligence and responsibly contributing to this rapidly evolving field. Author Contributions Amogh Verma: writing – original draft, writing – review and editing. Prerna Uniyal: conceptualization, methodology, validation, supervision, project administration, writing – original draft, writing – review and editing. Sayanti Pandey Banerjee: writing – original draft, writing – review and editing. Funding The authors received no specific funding for this work. Ethics Statement The authors have nothing to report. Consent Consent to participate is not applicable as no patient data were collected or analyzed in this study. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments Generative AI tools, including Paperpal and ChatGPT 5, were utilized solely for language, grammar, and stylistic refinement. These tools had no role in the conceptualization, data analysis, interpretation of results, or substantive content development of this manuscript. All intellectual contributions, data analysis, and scientific interpretations remain the sole work of the authors. The final content was critically reviewed and edited to ensure accuracy and originality. The authors take full responsibility for the accuracy, originality, and integrity of the work presented. Data Availability Statement The authors have nothing to report. References Associated Data Data Availability Statement The authors have nothing to report.